CME

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom...

Faculty: Brendon Neuen, MBBS, PhD Faculty: Katherine Tuttle, MD A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may...

Faculty: Jose Rubio, MD Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse effects that affect adherence. Emerging evidence supports a role for muscarinic M₁/M₄ receptor dysfunction in schizophrenia, leading to the development of therapies with mechanisms distinct from dopamine blockade....

Faculty: Prem S. Subramanian, MD, PhD Faculty: Andrea Lora Kossler, MD, FACS Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered...

Faculty: Andrea Lora Kossler, MD, FACS Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care....

Faculty: Prem S. Subramanian, MD, PhD Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care....

Faculty: Prem S. Subramanian, MD, PhD Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care....

Faculty: Andrea Lora Kossler, MD, FACS Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care....